Trials / Completed
CompletedNCT04854590
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 248 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
Detailed description
To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.
Conditions
Timeline
- Start date
- 2021-04-22
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
- First posted
- 2021-04-22
- Last updated
- 2024-07-24
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04854590. Inclusion in this directory is not an endorsement.